A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2006, Pages 99-106

  Manesis, E K ^a   Papatheodoridis, G V ^a   Hadziyannis, S J ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED;

EID: 33644886354     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02731.x     Document Type: Article

References (39)

1. Ganem D Prince AM Hepatitis B virus infection - natural history and clinical consequences N Engl J Med 2004 350 1118 29
2. Lai CL Ratziu V Yuen MF Poynard T Viral hepatitis B Lancet 2003 362 2089 94
3. Papatheodoridis GV Hadziyannis SJ Current management of chronic hepatitis B Aliment Pharmacol Ther 2004 19 25 37
4. Dooley JS Davis GL Peters M Waggoner JG Goodman Z Hoofnagle JH Pilot study of recombinant human alpha-interferon for chronic type B hepatitis Gastroenterology 1986 90 150 7
5. Cooksley WG Treatment with interferons (including pegylated interferons) in patients with hepatitis B Semin Liver Dis 2004 24 Suppl. 1 45 53
6. Brunetto MR Oliveri F Colombatto P Coco B Ciccorossi P Bonino F Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon J Hepatol 2003 39 Suppl. 1 S164 7
7. Hadziyannis SJ Papatheodoridis GV Emerging treatments in chronic hepatitis B Expert Opin Emerg Drugs 2004 9 207 21
8. Hadziyannis SJ Tassopoulos NC Heathcote EJ et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 2003 348 800 7
9. Papatheodoridis GV Dimou E Laras A Papadimitropoulos V Hadziyannis SJ Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease Hepatology 2002 36 219 26
10. Laras A Koskinas J Avgidis K Hadziyannis SJ Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients J Viral Hepat 1998 5 241 8
11. Miyakawa Y Mizokami M Classifying hepatitis B virus genotypes Intervirology 2003 46 329 38
12. Leung N Treatment of chronic hepatitis B: case selection and duration of therapy J Gastroenterol Hepatol 2002 17 409 14
13. Manesis EK Hadziyannis SJ Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B Gastroenterology 2001 121 101 9
14. Lampertico P Del Ninno E Vigano M et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 2003 37 756 63
15. Marcellin P Lau GK Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B; Peginterferon Alfa-2a HBeAg-negative Chronic Hepatitis B Study Group N Engl J Med 2004 351 1206 17
16. Akarca US Ersoz G Gunsar F et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B Antivir Ther 2004 9 325 34
17. Schiefke I Klecker C Maier M et al. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a Liver Int 2004 24 98 104
18. Jaboli MF Fabbri C Liva S et al. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial World J Gastroenterol 2003 9 1491 5
19. Yalcin K Degertekin H Yildiz F Celik Y Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B Clin Infect Dis 2003 36 1516 22
20. Santantonio T Niro GA Sinisi E et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study J Hepatol 2002 36 799 804
21. Tatulli I Francavilla R Rizzo GL et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B J Hepatol 2001 35 805 10
22. Barbaro G Zechini F Pellicelli AM et al. Lamivudine Italian Study Group Investigators Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial J Hepatol 2001 35 406 11
23. Serfaty L Thabut D Zoulim F et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study Hepatology 2001 34 573 7
24. Mutimer D Dowling D Cane P et al. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection Antivir Ther 2000 5 273 7
25. Schalm SW Heathcote J Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial Gut 2000 46 562 8
26. Gerken G Gomez J Lambertico P et al. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay J Virol Methods 1998 74 155 65
27. Ishak K Baptista A Bianchi L et al. Histological grading and staging of chronic hepatitis J Hepatol 1995 22 696 9
28. de Franchis R Hadengue A Lau G et al. EASL Jury EASL International Consensus Conference on Hepatitis B 13-14 September 2002, Geneva, Switzerland. Consensus Statement (long version) J Hepatol 2003 39 Suppl. 1 S3 25
29. Lok AS McMahon BJ Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations Hepatology 2004 39 857 61
30. Hadziyannis SJ Papatheodoridis GV Dimou E Laras A Papaioannou C Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen negative chronic hepatitis B Hepatology 2000 32 847 51
31. Yurdaydin C Bozkaya H Cetinkaya H et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B J Viral Hepat 2005 12 262 8
32. Hasan F al-Khaldi J Asker H et al. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine Hepatogastroenterology 2003 50 2040 2
33. Schiff ER Dienstag JL Karayalcin S et al. International Lamivudine Investigator Group Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders J Hepatol 2003 38 818 26
34. Korba BE Cote P Hornbuckle W et al. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks Antivir Ther 2000 5 95 104
35. Lok AS Heathcote EJ Hoofnagle JH Management of hepatitis B: 2000 - summary of a workshop Gastroenterology 2001 120 1828 53
36. Papatheodoridis GV Manesis E Hadziyannis SJ The long-term outcome of interferon treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 2001 34 306 13
37. Manesis EK Papatheodoridis GV Hadziyannis SJ Serum HBV-DNA levels in inactive hepatitis B virus carriers Gastroenterology 2002 122 2092 3
38. Manesis EK Papatheodoridis GV Sevastianos V Cholongitas E Papaioannou C Hadziyannis SJ Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection Am J Gastroenterol 2003 98 2261 7
39. Marcellin P Lau GKK Bonino F et al. Sustained response to peginterferon α-2a (40 kDa) (Pegasys®) in HBeAg-negative chronic hepatitis B. 1 year follow-up data from a large, randomized multinational study (abstract) J Hepatol 2005 42 Suppl. 2 185 6